The Role of HIV-1 Drug-Resistant Minority Variants in Treatment Failure

Natalia Stella-Ascariz, José Ramón Arribas, Roger Paredes, Jonathan Z. Li

    Research output: Contribution to journalArticleResearchpeer-review

    22 Citations (Scopus)

    Abstract

    © 2017 Author(s). Human immunodefciency virus type 1 (HIV-1) drug resistance genotyping is recommended to help in the selection of antiretroviral therapy and to prevent virologic failure. Tere are several ultrasensitive assays able to detect HIV-1 drug-resistance minority variants (DRMVs) not detectable by standard population sequencing-based HIV genotyping assays. Presence of these DRMVs has been shown to be clinically relevant, but its impact does not appear to be uniform across drug classes. In this review, we summarize key evidence for the clinical impact of DRMVs across drug classes for both antiretroviral treatment-naive and antiretroviral treatment-experienced patients, and highlight areas where more supporting evidence is needed.
    Original languageEnglish
    Pages (from-to)S847-S850
    JournalJournal of Infectious Diseases
    Volume216
    DOIs
    Publication statusPublished - 1 Jan 2017

    Keywords

    • drug resistant minority variants
    • HIV-1 drug resistance
    • treatment failure

    Fingerprint

    Dive into the research topics of 'The Role of HIV-1 Drug-Resistant Minority Variants in Treatment Failure'. Together they form a unique fingerprint.

    Cite this